Voyageur Pharmaceuticals Ltd.
VYYRF
$0.0991
-$0.0069-6.51%
| Weiss Ratings | VYYRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | VYYRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | VYYRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 41.23 | |||
| Price History | VYYRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -6.51% | |||
| 30-Day Total Return | -33.93% | |||
| 60-Day Total Return | 4,855.00% | |||
| 90-Day Total Return | 98.20% | |||
| Year to Date Total Return | 26.89% | |||
| 1-Year Total Return | 19,720.00% | |||
| 2-Year Total Return | 62.99% | |||
| 3-Year Total Return | -6.07% | |||
| 5-Year Total Return | 71.75% | |||
| 52-Week High % Change | -50.45% | |||
| 52-Week Low % Change | 4,855.00% | |||
| Price | VYYRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.20 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Nov 27, 2024 | |||
| 52-Week High Price (Date) | Jan 28, 2025 | |||
| Valuation | VYYRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 14.25M | |||
| Enterprise Value | 14.28M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.01 | |||
| Earnings Per Share Growth | -18.63% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 19.82 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.10 | |||
| Enterprise Value/EBITDA (TTM) | -15.04 | |||
| Enterprise Value/EBIT | -15.02 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | VYYRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 139.45M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | VYYRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | -- | |||
| Address | 4103B Center Street Calgary, AB T2E 2Y6 | |||
| Website | voyageurpharmaceuticals.ca | |||
| Country | Canada | |||
| Year Founded | -- | |||
| Profitability | VYYRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | VYYRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -36.87% | |||
| Return on Equity | -- | |||
| Income Statement | VYYRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -982.70K | |||
| EBIT (TTM) | -984.00K | |||
| Net Income (TTM) | -1.13M | |||
| Net Income Avl. to Common (TTM) | -1.13M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -167.28% | |||
| EPS Diluted (TTM) | -0.01 | |||
| EPS Diluted Growth (Q YOY) | -171.43% | |||
| Balance Sheet | VYYRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 4.80K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 96.30K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 700.10K | |||
| Current Ratio (Q) | 0.097 | |||
| Book Value Per Share (Q) | $0.01 | |||
| Total Assets (Q) | 1.73M | |||
| Total Current Liabilities (Q) | 989.80K | |||
| Total Debt (Q) | 29.60K | |||
| Total Liabilities (Q) | 1.03M | |||
| Total Common Equity (Q) | 700.10K | |||
| Cash Flow | VYYRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -120.40K | |||
| Cash from Financing (TTM) | 385.50K | |||
| Net Change in Cash (TTM) | 3.40K | |||
| Levered Free Cash Flow (TTM) | 200.50K | |||
| Cash from Operations (TTM) | -261.60K | |||
